<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: highly dependent on successfully selling", fill: "#ff5349"},
{source: "2: highly dependent on successfully selling", target: "2: regulatory approval", fill: "#ff5349"},
{source: "2: highly dependent on successfully selling", target: "3: regulatory", fill: "#ff9f00"},
{source: "3: regulatory", target: "3: clearances", fill: "#ff9f00"},
{source: "3: clearances", target: "3: United States ", fill: "#ff9f00"},
{source: "3: United States ", target: "3: development", fill: "#ff9f00"},
{source: "3: regulatory", target: "6: dependent upon", fill: "#fada5e"},
{source: "6: dependent upon", target: "6: ancillary", fill: "#fada5e"},
{source: "6: ancillary", target: "6: operations", fill: "#fada5e"},
{source: "6: dependent upon", target: "18: manufacturing", fill: "#bfff00"},
{source: "18: manufacturing", target: "20: manufacture", fill: "#900"},
{source: "20: manufacture", target: "20: regulatory", fill: "#900"},
{source: "20: regulatory", target: "20: requirements", fill: "#900"},
{source: "20: requirements", target: "20: which could", fill: "#900"},
{source: "20: which could", target: "20: inability", fill: "#900"},
{source: "20: manufacture", target: "131: strategic reserve supplies", fill: "#bdb76b"},
{source: "131: strategic reserve supplies", target: "131: each significant singlesourced", fill: "#bdb76b"},
{source: "131: each significant singlesourced", target: "131: manufacture", fill: "#bdb76b"},
{source: "131: manufacture", target: "131: future may", fill: "#bdb76b"},
{source: "131: future may", target: "131: financing agreement with", fill: "#bdb76b"},
{source: "131: financing agreement with", target: "131: in the Royalty Trust", fill: "#bdb76b"},
{source: "131: strategic reserve supplies", target: "START_HERE", fill: "#bdb76b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Apparel Accessories and Luxury Goods</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Security_clearance">Security clearance</a></td>
      <td>A security clearance is a status granted to individuals allowing them access to classified information (state or organizational secrets) or to restricted areas, after completion of a thorough background check. The term "security clearance" is also sometimes used in private organizations that have a formal process to vet employees for access to sensitive information.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Q_clearance">Q clearance</a></td>
      <td>Q clearance or Q access authorization is the U.S. Department of Energy (DOE) security clearance required to access Top Secret Restricted Data, Formerly Restricted Data, and National Security Information, as well as Secret Restricted Data. Restricted Data (RD) is defined in the Atomic Energy Act of 1954 and covers nuclear weapons and related materials.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lowland_Clearances">Lowland Clearances</a></td>
      <td>The Lowland Clearances were one of the results of the Scottish Agricultural Revolution, which changed the traditional system of agriculture which had existed in Lowland Scotland in the seventeenth century. Thousands of cottars and tenant farmers from the southern counties (Lowlands) of Scotland migrated from farms and small holdings they had occupied to the new industrial centres of Glasgow, Edinburgh and northern England  or abroad, or remaining upon land though adapting to the Scottish Agricultural Revolution.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clearance_rate">Clearance rate</a></td>
      <td>In criminal justice, clearance rate is calculated by dividing the number of crimes that are "cleared" (a charge being laid) by the total number of crimes recorded. Clearance rates are used by various groups as a measure of crimes solved by the police.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/DMG_Clearances">DMG Clearances</a></td>
      <td>DMG Clearances, Inc is a company based in Hockessin, Delaware, USA, which handles music clearances and licensing for the entertainment industry. DMG Clearances was founded in 1996 by Deborah Mannis-Gardner.The company clears musical compositions for use in films, video games, sampling and Broadway Theater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/L_clearance">L clearance</a></td>
      <td>An L clearance is a security clearance used by the United States Department of Energy (DOE) and Nuclear Regulatory Commission for civilian access relating to nuclear materials and information under the Atomic Energy Act of 1954. It is equivalent to a United States Department of Defense (DOD) Secret clearance.The DOE L clearance provides less access than the agency's Q clearance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_U.S._security_clearance_terms">List of U.S. security clearance terms</a></td>
      <td>This is a list of security clearance terms used in the United States of America.\nSecurity clearance levels are used to control access to information that should not be freely available to all.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Slum_clearance">Slum clearance</a></td>
      <td>Slum clearance, slum eviction or slum removal is an urban renewal strategy used to transform low income settlements with poor reputation into another type of development or housing. This has long been a strategy for redeveloping urban communities; for example slum clearance plans were required in the United Kingdom in the Housing Act 1930, while the Housing Act of 1937 encouraged similar clearance strategies in the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Royalty_trust">Royalty trust</a></td>
      <td>A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. However, unlike most corporations, its profits are not taxed at the corporate level provided a certain high percentage (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/BP_Prudhoe_Bay_Royalty_Trust">BP Prudhoe Bay Royalty Trust</a></td>
      <td>The BP Prudhoe Bay Royalty Trust is a United States oil and natural gas royalty trust based in New York, New York.  With a market capitalization of US$155 million in early 2020, and an average trading volume of 322,000 shares, BP Prudhoe Bay Royalty Trust is the largest conventional oil and gas trust in the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Permian_Basin_Royalty_Trust">Permian Basin Royalty Trust</a></td>
      <td>The Permian Basin Royalty Trust (NYSE: PBT) is a United States oil and natural gas royalty trust based in Dallas, Texas.  With a market capitalization of US $790,000,000, and an average daily trading volume of about 186,000 shares at the end of 2007, it was one of the largest royalty trusts in the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nauru_Phosphate_Royalties_Trust">Nauru Phosphate Royalties Trust</a></td>
      <td>The Nauru Phosphate Royalties Trust (NPRT) was a sovereign wealth fund developed by the government of the Republic of Nauru in which the government invested money from the state-owned mining company, Nauru Phosphate Corporation. This money was then re-invested in a real estate portfolio, among other things, to provide the government with a reliable national income following the depletion of minable phosphates on the island.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Income_trust">Income trust</a></td>
      <td>An income trust is an investment that may hold equities, debt instruments, royalty interests or real properties. They are especially useful for financial requirements of institutional investors such as pension funds, and for investors such as retired individuals seeking yield.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Royalty_fund">Royalty fund</a></td>
      <td>A royalty fund (also known as royalty funding) is a category of private equity fund that specializes in purchasing consistent revenue streams deriving from the payment of royalties. One growing subset of this category is the healthcare royalty fund, in which a private equity fund manager purchases a royalty stream paid by a pharmaceutical company to a patent holder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pengrowth_Energy">Pengrowth Energy</a></td>
      <td>Pengrowth Energy Corporation was a Canadian oil and natural gas company based in Calgary, Alberta.  Established in 1988 by Calgary entrepreneur James S Kinnear, it was one of the largest of the Canadian royalty trusts ("Canroys"), with a market capitalization of US$4.12 billion at the end of 2007.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Obsidian_Energy">Obsidian Energy</a></td>
      <td>Obsidian Energy Ltd. (previously known as Penn West Exploration Ltd., Penn West Petroleum and Penn West Energy Trust) is a mid-sized Canadian oil and natural gas production company based in Calgary, Alberta.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ORTHOVITA INC      ITEM 1A RISK FACTORS        If VITOSS is not <font color="blue">commercially successful</font> in the <font color="blue">United States </font>or if CORTOSS     and  VITOSS are not <font color="blue">commercially successful</font> in the <font color="blue">European Union</font>, our     operating results will be impaired</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">highly dependent</font> on successfully selling</font> our products for which we     have  received  <font color="blue"><font color="blue">regulatory</font> approval</font> or clearance</td>
    </tr>
    <tr>
      <td>We expect <font color="blue">regulatory</font>     approvals  or  <font color="blue">clearances</font>  in the <font color="blue">United States </font>for our <font color="blue">products under</font>     <font color="blue">development</font>, if obtained at all, to take several years</td>
    </tr>
    <tr>
      <td>To date, we have     received <font color="blue"><font color="blue">regulatory</font> approval</font> to market VITOSS, CORTOSS and ALIQUOT for     <font color="blue">specified uses</font> in the <font color="blue">European Union</font>, Australia and countries adhering to     the  <font color="blue">regulatory</font> standards <font color="blue">of the <font color="blue">European Union</font></font></td>
    </tr>
    <tr>
      <td>We have also received     <font color="blue">regulatory</font> clearance to market VITOSS and IMBIBE in the United States</td>
    </tr>
    <tr>
      <td>For     these reasons, we are <font color="blue">dependent upon</font> VITOSS and CORTOSS and their <font color="blue">ancillary</font>     products,  IMBIBE and ALIQUOT, in their respective approved markets to     generate sufficient revenues to sustain <font color="blue">operations</font> in the future</td>
    </tr>
    <tr>
      <td>These products have <font color="blue">only been recently approved</font> or cleared and launched, and     the markets for our products are evolving</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot accurately</font>     <font color="blue">predict either</font> the <font color="blue">future growth rate</font> of <font color="blue">product sales</font>, if any, or the     <font color="blue">ultimate size</font> of these markets</td>
    </tr>
    <tr>
      <td>Certain factors that may limit our ability     to <font color="blue">increase sales</font> include:           •   our <font color="blue">dependence on</font> the efforts of <font color="blue">independent</font> agents and <font color="blue"><font color="blue">distributor</font>s</font>     to promote the use of our products, over which we have limited control;           •   the <font color="blue">introduction</font> of <font color="blue"><font color="blue">new products</font> into</font> the <font color="blue">market by competing</font>     <font color="blue"><font color="blue">orthopedic companies</font> based upon</font> other <font color="blue">competing <font color="blue">technologies</font></font>;           •   our <font color="blue">dependence on</font> the <font color="blue">continued <font color="blue">publication</font></font> of <font color="blue">independent</font>     pre-clinical and <font color="blue">clinical data</font> to support the use of our products;           •   our need to train a sufficient number of surgeons to create demand for     our products; and           •   the need for payors to <font color="blue">authorize insurance <font color="blue">reimbursement</font></font> for     <font color="blue">procedures using</font> our products</td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of our <font color="blue">products will largely depend on</font> our ability to     <font color="blue">demonstrate</font> their relative safety, efficacy, cost-<font color="blue">effective</font>ness and ease of     use</td>
    </tr>
    <tr>
      <td>Surgeons will not use our products unless they determine, <font color="blue">based on</font>     experience, <font color="blue">clinical data</font> and <font color="blue">recommendations from prominent surgeons</font> and     mentors that our products are safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">based on</font>     <font color="blue">new <font color="blue">technologies</font></font> that have not <font color="blue">been previously used</font> and <font color="blue">must compete with</font>     more <font color="blue">established treatments currently accepted as</font> the standards of care</td>
    </tr>
    <tr>
      <td>The     <font color="blue">attributes</font> of some of our <font color="blue">products may</font> require some changes in surgical     <font color="blue">techniques</font> that have become standard within the <font color="blue">medical <font color="blue">community</font></font>, and there     may be resistance to change</td>
    </tr>
    <tr>
      <td>Therefore, for these products, we must be able     to convince surgeons who currently favor existing <font color="blue">techniques</font> to switch to     new procedures that would use our products</td>
    </tr>
    <tr>
      <td>Many <font color="blue">surgeons will</font> not purchase     our <font color="blue">products until there</font> is sufficient, long-term clinical evidence to     convince  them to alter their <font color="blue">existing treatment methods</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">surgeons may</font> be slow to change their <font color="blue">medical treatment practices</font> because of     perceived <font color="blue"><font color="blue">liability</font> risks</font> arising from the use of <font color="blue">new products</font> and the     <font color="blue">uncertainty</font>                                           21     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>of <font color="blue">third party</font> <font color="blue">reimbursement</font> for our products</td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue">gain market</font>     <font color="blue">acceptance</font> of our <font color="blue">products could</font> result in <font color="blue">lower sales</font> and the <font color="blue">inability</font> to     <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Our plan to assume <font color="blue">manufacturing</font> of VITAGEL and its related <font color="blue">products may</font> not     be successful or timely</td>
    </tr>
    <tr>
      <td>Pursuant to our <font color="blue">Exclusive Sales Distribution Agreement </font>with Angiotech, as     amended, we expect to assume full <font color="blue">manufacturing</font> for the VITAGEL <font color="blue">product upon</font>     <font color="blue">approval from</font> the <font color="blue">FDA of the PMA </font>we submitted in <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>There can be     no assurance that we will receive FDA approval to <font color="blue">manufacture</font> VITAGEL or     that,  even if approved, we will be able to <font color="blue">comply with</font> FDA <font color="blue">regulatory</font>     <font color="blue">requirements</font> to continue to <font color="blue">manufacture</font> VITAGEL, <font color="blue">which could</font> result in delay     or <font color="blue">inability</font> to <font color="blue">manufacture</font> and sell the products</td>
    </tr>
    <tr>
      <td>There can be no assurance     that we will receive any <font color="blue">such approval prior</font> to <font color="blue">running out</font> of the limited     product we purchased to sell that was <font color="blue">manufacture</font>d by <font color="blue">Angiotech </font>prior to     their <font color="blue">shutting down</font> their <font color="blue">manufacturing</font> <font color="blue">facility</font> in November 2005</td>
    </tr>
    <tr>
      <td>If we are unable to operate an <font color="blue">effective</font> sales and <font color="blue"><font color="blue">distribution</font> network</font>, our     ability to <font color="blue">generate sales</font> and <font color="blue">become profitable</font> will be impaired</td>
    </tr>
    <tr>
      <td>We have assembled a <font color="blue">field sales</font> network of <font color="blue">independent</font> <font color="blue">sales agencies</font> and     <font color="blue">direct sales <font color="blue">representatives</font></font> <font color="blue">in the US </font>in order to market VITOSS Bone     Graft Substitute, VITAGEL and IMBIBE Outside of the US, we utilize a     network of <font color="blue">independent</font> stocking <font color="blue"><font color="blue">distributor</font>s</font> to market VITOSS Bone Graft     Substitute, CORTOSS and ALIQUOT We seek to strengthen our <font color="blue">field sales</font>     <font color="blue">network through</font> the addition of <font color="blue">direct sales <font color="blue">representatives</font></font> in those US     <font color="blue">territories</font> where we either do not have <font color="blue">independent</font> sales agency coverage or     the <font color="blue">territories</font> are underserved</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent upon</font> our <font color="blue"><font color="blue">distributor</font>s</font>,     sales  agencies  and  <font color="blue">direct sales <font color="blue">representatives</font></font> for the sale of our     products</td>
    </tr>
    <tr>
      <td>Any failure to maintain and <font color="blue">effective</font>ly manage our <font color="blue">distribution</font>     <font color="blue">network will impair</font> our ability to <font color="blue">generate <font color="blue">additional</font> sales</font> and become     profitable</td>
    </tr>
    <tr>
      <td>There can be no assurance that the <font color="blue"><font color="blue">distributor</font>s</font> and <font color="blue">agencies will</font> perform     their <font color="blue"><font color="blue">obligation</font>s</font> in their respective <font color="blue">territories</font> as expected, or that we     <font color="blue">will continue</font> to derive any <font color="blue">revenue from</font> these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We cannot     assure  that our interests <font color="blue">will continue</font> to <font color="blue">coincide with</font> those of our     <font color="blue"><font color="blue">distributor</font>s</font>  and  agencies</td>
    </tr>
    <tr>
      <td>In  addition,  we <font color="blue">cannot assure</font> that our     <font color="blue"><font color="blue">distributor</font>s</font> and <font color="blue">agencies will</font> not develop <font color="blue">independent</font>ly, or with other     companies, other <font color="blue"><font color="blue">competitive</font> products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">independent</font> US <font color="blue">agencies selling</font> VITOSS Bone Graft Substitute <font color="blue">generally</font>     <font color="blue"><font color="blue">sell products</font> from</font> other <font color="blue">orthopedic companies</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">single agency may sell</font>     VITOSS Bone Graft Substitute, as well as hardware <font color="blue">manufacture</font>d by other     <font color="blue">orthopedic companies</font> consisting of metal plates, screws and <font color="blue">titanium spinal</font>     cages, to end <font color="blue">user hospitals</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales could</font> be <font color="blue"><font color="blue">adversely affect</font>ed</font> if, for     any reason, one or more of our <font color="blue">successful agencies lost</font> their hardware     <font color="blue">product line provided by</font> other <font color="blue">orthopedic companies</font></td>
    </tr>
    <tr>
      <td>Additionally, our     <font color="blue">independent</font> agencies may be unable or unwilling to carry or <font color="blue">effective</font>ly sell     VITOSS Bone Graft Substitute as a result of the <font color="blue">introduction</font> of <font color="blue">new products</font>     into the <font color="blue">market based upon</font> other <font color="blue">technologies</font> that <font color="blue">could compete with</font> VITOSS     Bone Graft Substitute</td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales could</font> be <font color="blue"><font color="blue">adversely affect</font>ed</font> if one or more     of our <font color="blue">successful agencies eliminated</font> VITOSS Bone Graft Substitute from     their  product  line  for any other reason and terminated their agency     <font color="blue">arrangement with us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales could</font> also be <font color="blue"><font color="blue">adversely affect</font>ed</font> if our     <font color="blue">independent</font> agencies become concerned that their agency <font color="blue">arrangement with us</font>     could be <font color="blue">eliminated as</font> a result of another company’s offer or threat to     acquire us</td>
    </tr>
    <tr>
      <td>The complete <font color="blue">product line represented by</font> the <font color="blue"><font color="blue">distributor</font>s</font> and     agencies,  including  our  products,  is  an  important  factor in the     <font color="blue"><font color="blue">distributor</font>s</font>’ or agencies’ ability to penetrate the market</td>
    </tr>
    <tr>
      <td>Accordingly, our     ability to penetrate the markets that we intend to serve is <font color="blue">highly dependent</font>     upon the quality and breadth of the other <font color="blue">product lines</font> carried by our     <font color="blue"><font color="blue">distribution</font> network</font>, the <font color="blue">components</font> of which may change from time to time,     and over which we have little or no control</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>In an effort to further <font color="blue">accelerate</font> the growth of sales, we continue to build     our  sales <font color="blue">management</font> team and add <font color="blue">direct sales <font color="blue">representatives</font></font> to our     <font color="blue">organization</font> for certain open or underserved <font color="blue">territories</font> <font color="blue"><font color="blue">in the US </font>The     </font>addition  of  <font color="blue">direct sales <font color="blue">representatives</font></font> will increase our operating     expenses</td>
    </tr>
    <tr>
      <td>Furthermore, there is no assurance that <font color="blue">adding direct sales</font>     <font color="blue">representatives</font> will improve sales or that our <font color="blue">direct sales <font color="blue">representatives</font></font>     will be successful in <font color="blue">generating sufficient sales</font> to cover the cost of     supporting their <font color="blue">sales <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>There is no assurance that we will be     able  to  attract and retain <font color="blue">qualified personnel</font> to market or sell our     products or that we <font color="blue">will successfully</font> implement this type of sales and     <font color="blue">distribution</font> method</td>
    </tr>
    <tr>
      <td>The unapproved or “off-label” use of our <font color="blue">products could</font> <font color="blue">adversely affect</font> the     reputation of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">medical devices</font> that we <font color="blue">manufacture</font> and market, or intend to market, are     subject to extensive <font color="blue">regulation by</font> the FDA, the <font color="blue"><font color="blue">European Union</font> </font>Medical     Devices Directive and other worldwide <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>In order to     market our products, we must apply for, receive and maintain all <font color="blue">necessary</font>     <font color="blue"><font color="blue">regulatory</font> approval</font>s or <font color="blue">clearances</font> in <font color="blue">each applicable jurisdiction</font> for     <font color="blue">specified uses</font> of the products</td>
    </tr>
    <tr>
      <td><font color="blue">Under FDA </font><font color="blue">regulations</font>, we are <font color="blue">only permitted</font>     to  <font color="blue">commercially distribute</font> our products for approved indication(s) or     use(s); failure to <font color="blue">comply with</font> these <font color="blue">regulations</font> may subject us to FDA     <font color="blue">enforcement action</font></td>
    </tr>
    <tr>
      <td>CORTOSS received CE Certification, an <font color="blue">international</font> symbol of adherence to     quality assurance standards and <font color="blue">compliance with</font> applicable European medical     device  <font color="blue">directives</font>,  in  <font color="blue">January  </font>2003  for use in <font color="blue">repairing vertebral</font>     <font color="blue"><font color="blue">compression</font> fractures</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">surgeons may</font> have attempted to use CORTOSS     “off-label”  in  procedures  to repair vertebral <font color="blue"><font color="blue">compression</font> fractures</font>     performed prior to the <font color="blue">European Union</font>’s approval of CORTOSS for this type of     procedure</td>
    </tr>
    <tr>
      <td>Furthermore, all surgeons have not <font color="blue">been trained</font> in the proper use     of CORTOSS to repair vertebral <font color="blue"><font color="blue">compression</font> fractures</font> since the European     Union <font color="blue">only recently approved</font> the use of CORTOSS for that type of procedure</td>
    </tr>
    <tr>
      <td>A surgeon who has not <font color="blue">been <font color="blue">properly trained</font></font> to use CORTOSS in a procedure to     repair vertebral <font color="blue"><font color="blue">compression</font> fractures</font> could pose a risk to the reputation     of our CORTOSS product</td>
    </tr>
    <tr>
      <td>In addition, the occurrence of an <font color="blue">adverse event</font>     <font color="blue">while using</font> our product “off-label” in procedures other than the repair of     vertebral <font color="blue"><font color="blue">compression</font> fractures</font> or <font color="blue">screw <font color="blue">augmentation</font> could <font color="blue">adversely affect</font></font>     the reputation of CORTOSS or any of our other <font color="blue">products as well as us</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">successfully train</font> a sufficient number of surgeons, demand for     our <font color="blue">products could</font> be <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>It  is  critical  to  the  <font color="blue">commercial success</font> of our products that our     <font color="blue">independent</font> <font color="blue"><font color="blue">distributor</font>s</font>, agents and <font color="blue">direct sales <font color="blue">representatives</font></font> succeed in     training a sufficient number of surgeons and in <font color="blue">providing them adequate</font>     <font color="blue">instruction</font> in the use of our products</td>
    </tr>
    <tr>
      <td>This training requires a <font color="blue">commitment</font>     of time and <font color="blue">money by surgeons</font> that they may be unwilling to give</td>
    </tr>
    <tr>
      <td>Even if     surgeons are willing, if they are not <font color="blue">properly trained</font>, they may misuse or     in<font color="blue">effective</font>ly use our products</td>
    </tr>
    <tr>
      <td>This may result in unsatisfactory patient     outcomes, patient injury, negative publicity or <font color="blue">lawsuits against us</font>, any of     <font color="blue">which could</font> damage our business and reduce <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>If  health  <font color="blue">care providers cannot</font> obtain third-party <font color="blue">reimbursement</font> for     <font color="blue">procedures using</font> our products, or if such <font color="blue">reimbursement</font> is inadequate, we     may never <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font>sales of our products in the <font color="blue">United States </font>and other <font color="blue">markets will</font>     depend  on the <font color="blue">availability</font> of adequate <font color="blue">reimbursement</font> from third-party     payors</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font>providers, such as hospitals and surgeons that purchase     medical  devices  for  treatment  of their patients, <font color="blue">generally</font> rely on     third-party payors to reimburse all or part of the costs and <font color="blue">fees associated</font>     with the procedures performed with these devices</td>
    </tr>
    <tr>
      <td>Both public and private     insurance  <font color="blue">reimbursement</font>  plans are central to new product <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font><font color="blue">providers may refuse</font> to use our products if <font color="blue">reimbursement</font> is     inadequate</td>
    </tr>
    <tr>
      <td>We do not yet know how <font color="blue">reimbursement</font> will be handled for all of     our products because some procedures that use our products are new and     <font color="blue">reimbursement</font> policies regarding these procedures have not <font color="blue">been finalized</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inadequate </font><font color="blue">reimbursement</font> by private insurance companies and <font color="blue">government</font>     <font color="blue">programs could <font color="blue">significant</font>ly reduce usage</font> of our products</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>In addition, an <font color="blue">increasing emphasis on managed care</font> in the <font color="blue">United States </font>has     placed, and we believe <font color="blue">will continue</font> to place, <font color="blue">greater pressure on medical</font>     device pricing</td>
    </tr>
    <tr>
      <td>Such <font color="blue">pressures could</font> have a material adverse effect on our     ability to sell our <font color="blue">products profitably</font></td>
    </tr>
    <tr>
      <td>We could be <font color="blue">negatively impacted by future interpretation</font> or <font color="blue">implementation</font>     of federal and state fraud and <font color="blue">abuse laws</font>, including anti-kickback laws and     false claims laws</td>
    </tr>
    <tr>
      <td>To the extent that our products receive <font color="blue">government</font> <font color="blue">reimbursement</font>, we are     subject to various federal and state laws pertaining to health care fraud     and abuse, including anti-kickback laws and false claims laws</td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of     these laws are punishable by criminal and/or civil sanctions, including, in     some instances, <font color="blue">imprisonment</font> and exclusion from <font color="blue">participation</font> in federal and     state health care programs, including Medicare, Medicaid, and veterans’     health programs</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">been challenged by</font> a <font color="blue">government</font>al authority     under any of these laws and believe that our <font color="blue">operations</font> are in compliance     <font color="blue">with such laws</font></td>
    </tr>
    <tr>
      <td>Health  care  fraud and abuse <font color="blue">regulations</font> are complex, and <font color="blue">even minor</font>,     <font color="blue">inadvertent irregularities</font> can <font color="blue">potentially give rise</font> to claims that the law     has <font color="blue">been violated</font></td>
    </tr>
    <tr>
      <td>Any violations of these laws could result in a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If there is a change in law, regulation or <font color="blue">administrative</font> or     <font color="blue">judicial <font color="blue">interpretations</font></font>, we may have to change our business practices or     our existing business <font color="blue">practices could</font> be challenged as unlawful, <font color="blue">which could</font>     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could become</font> subject to false claims <font color="blue"><font color="blue">litigation under</font> federal</font> or state     statutes,  which can lead to civil money penalties, criminal fines and     <font color="blue">imprisonment</font>, and/or exclusion from <font color="blue">participation</font> in <font color="blue">federal health care</font>     programs</td>
    </tr>
    <tr>
      <td>These false claims statutes include the federal False Claims Act,     <font color="blue">which allows</font> any person to <font color="blue">bring suit</font> alleging the false or <font color="blue">fraudulent</font>     submission of claims for <font color="blue">payment under federal programs</font> or other violations     of  the  statute and to share in any <font color="blue">amounts paid by</font> the entity to the     <font color="blue">government</font> in fines or settlement</td>
    </tr>
    <tr>
      <td>Such suits, known as qui tam actions,     have increased <font color="blue">significant</font>ly in <font color="blue">recent years</font> and have increased the risk     that companies like us may have to defend a false claim action</td>
    </tr>
    <tr>
      <td>We could     also become subject to similar false claims <font color="blue">litigation under</font> state statutes</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in defending any such action, such action may have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may  need  to  <font color="blue">raise <font color="blue"><font color="blue">additional</font> capital</font></font></td>
    </tr>
    <tr>
      <td>If we are unable to raise     <font color="blue"><font color="blue">additional</font> capital</font> in the future, our product <font color="blue">development</font> could be limited     and  our  long  <font color="blue">term viability may</font> be threatened; however, if we raise     <font color="blue"><font color="blue">additional</font> capital</font>, your <font color="blue">percentage ownership as</font> a <font color="blue">shareholder</font> of <font color="blue">Orthovita     </font>will  decrease and <font color="blue">constraints could</font> be <font color="blue">placed on</font> the operation of our     business</td>
    </tr>
    <tr>
      <td>We may seek to obtain <font color="blue"><font color="blue">additional</font> funds through equity</font> or <font color="blue">debt financings</font>, or     <font color="blue">strategic alliances</font> with third parties either alone or in <font color="blue"><font color="blue">combination</font> with</font>     equity or <font color="blue">debt financing <font color="blue"><font color="blue">investment</font>s</font></font></td>
    </tr>
    <tr>
      <td>There are factors that may cause our future capital <font color="blue">requirements</font> to be     <font color="blue">greater than</font> anticipated or could <font color="blue">accelerate</font> our need for funds including,     without limitation:           •   unforeseen <font color="blue">development</font>s during our pre-clinical and <font color="blue">clinical trials</font>;           •   delays in the timing of receipt of required <font color="blue"><font color="blue">regulatory</font> approval</font>s or     <font color="blue">clearances</font> to make or <font color="blue">sell products</font>;           •   <font color="blue">unforeseen <font color="blue"><font color="blue">difficult</font>ies</font></font> in operating an <font color="blue">effective</font> direct sales and     <font color="blue"><font color="blue">distribution</font> network</font>;           •   <font color="blue">unanticipated expenditures</font> in research and product <font color="blue">development</font> or     <font color="blue">manufacturing</font> <font color="blue">activities</font>;           •   delayed, insufficient or lack of market <font color="blue">acceptance</font> of our products;           •   <font color="blue">unanticipated expenditures</font> in the <font color="blue">acquisition</font> and defense of     <font color="blue"><font color="blue">intellectual</font> property rights</font>;           •   the failure to develop <font color="blue">strategic alliances</font> for the marketing of some     of our products;           •   unforeseen changes in healthcare <font color="blue">reimbursement</font> for <font color="blue">procedures using</font>     our products;                                           24     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>  •   <font color="blue">inability</font> to <font color="blue">increase sales</font> of our approved or <font color="blue">cleared products</font>;           •   <font color="blue">inability</font> to train a sufficient number of surgeons to create demand     for our products;           •   lack of <font color="blue">financial resources</font> to <font color="blue">adequately support</font> our <font color="blue">operations</font>;           •   <font color="blue"><font color="blue">difficult</font>ies</font> in maintaining commercial scale <font color="blue">manufacturing</font> <font color="blue">capacity</font>     and <font color="blue">capability</font>;           •   <font color="blue">unforeseen problems</font> with our third-party <font color="blue">manufacture</font>rs and service     providers or with our <font color="blue">specialty suppliers</font> of <font color="blue"><font color="blue">certain raw</font> materials</font>;           •   unanticipated <font color="blue"><font color="blue">difficult</font>ies</font> in operating in <font color="blue"><font color="blue">international</font> markets</font>;           •   <font color="blue">inability</font> to meet our <font color="blue"><font color="blue">obligation</font>s</font> under our <font color="blue">revenue sharing <font color="blue">agreement</font></font>;           •   the need to respond to <font color="blue">technological</font> changes and increased     <font color="blue">competition</font>;           •   <font color="blue">unforeseen problems</font> in attracting and retaining <font color="blue">qualified personnel</font> to     market our products;           •   <font color="blue">enactment</font> of <font color="blue">new legislation</font> or <font color="blue">administrative</font> regulation;           •   the <font color="blue">application</font> to our business of <font color="blue">new court decisions</font> and <font color="blue">regulatory</font>     <font color="blue">interpretations</font>;           •   claims that might be brought in excess of our <font color="blue">insurance coverage</font>;           •   any imposition of penalties for failure to <font color="blue">comply with</font> <font color="blue">regulatory</font>     <font color="blue">guidelines</font>; or           •   <font color="blue">management</font>’s perception that <font color="blue">uncertainties</font> relating to these factors     may be increasing</td>
    </tr>
    <tr>
      <td>In addition, although we have no present <font color="blue">commitment</font>s or <font color="blue">understandings</font> to do     so,  we  may  seek  to  expand our <font color="blue">operations</font> and <font color="blue">product line through</font>     <font color="blue">acquisition</font>s or <font color="blue">joint ventures</font></td>
    </tr>
    <tr>
      <td>Any such <font color="blue">acquisition</font>s or <font color="blue">joint ventures</font> may     increase our capital <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain and maintain the <font color="blue"><font color="blue">regulatory</font> approval</font>s or <font color="blue">clearances</font>     <font color="blue">necessary</font> to make or sell our products, <font color="blue">sales could</font> be delayed or never     realized</td>
    </tr>
    <tr>
      <td>The <font color="blue">jurisdictions</font> in which we seek to market our products will regulate     these  products  as <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">most circumstances</font>, we and our     <font color="blue"><font color="blue">distributor</font>s</font> and <font color="blue">agents must</font> obtain <font color="blue">regulatory</font> <font color="blue">clearances</font>, approvals and     <font color="blue"><font color="blue">certification</font>s</font> and otherwise <font color="blue">comply with</font> extensive <font color="blue">regulations</font> regarding     safety, quality and <font color="blue">efficacy standards</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> vary from country     to  country,  and  the <font color="blue">regulatory</font> review can be lengthy, expensive and     uncertain</td>
    </tr>
    <tr>
      <td>We  may  not obtain or maintain the <font color="blue">regulatory</font> <font color="blue">clearances</font>,     approvals and <font color="blue"><font color="blue">certification</font>s</font> <font color="blue">necessary</font> to make or market our products in our     targeted  markets</td>
    </tr>
    <tr>
      <td>Moreover,  <font color="blue">regulatory</font>  <font color="blue">clearances</font>,  approvals  and     <font color="blue"><font color="blue">certification</font>s</font> that are obtained <font color="blue">may involve <font color="blue">significant</font> <font color="blue">restrictions</font> on</font> the     <font color="blue">anatomic sites</font> and types of procedures for which our products can be used</td>
    </tr>
    <tr>
      <td>In addition, we may be required to <font color="blue">incur <font color="blue">significant</font> costs</font> in obtaining or     maintaining our <font color="blue">regulatory</font> <font color="blue">clearances</font>, approvals and <font color="blue"><font color="blue">certification</font>s</font></td>
    </tr>
    <tr>
      <td>If we     do  not  obtain  or  maintain  <font color="blue">regulatory</font>  <font color="blue">clearances</font>,  approvals  and     <font color="blue"><font color="blue">certification</font>s</font> to <font color="blue">enable us</font> to make or market our products <font color="blue">in the US </font>or     elsewhere, or if the <font color="blue">clearances</font>, approvals and <font color="blue"><font color="blue">certification</font>s</font> are subject to     <font color="blue">significant</font> <font color="blue">restrictions</font>, we may never generate <font color="blue">significant</font> revenues</td>
    </tr>
    <tr>
      <td>The     <font color="blue">regulatory</font> <font color="blue">requirements</font> in some of the <font color="blue">jurisdictions</font> where we currently     market or intend to market our products are summarized below</td>
    </tr>
    <tr>
      <td><font color="blue">United States </font>       Regulation by <font color="blue">FDA The FDA </font>regulates the clinical testing, <font color="blue">manufacturing</font>,     labeling, <font color="blue">distribution</font> and promotion of <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>During 2002 and 2003, we received approval     from the FDA to conduct <font color="blue">two pilot <font color="blue">clinical studies</font></font> <font color="blue">in the US </font>to study the     use of CORTOSS in vertebral <font color="blue">augmentation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">two pilot <font color="blue">clinical studies</font></font> are     <font color="blue">fully enrolled</font> and we expect those trials to be completed by the end of     2006</td>
    </tr>
    <tr>
      <td>During 2004, we received <font color="blue">approval from</font> the FDA to conduct a pivotal     clinical study <font color="blue">in the US </font>to further study the use of CORTOSS in vertebral     <font color="blue">augmentation</font> using the <font color="blue">vertebroplasty</font> surgical technique</td>
    </tr>
    <tr>
      <td>We are still in     the process of completing <font color="blue">enrollment</font> of the <font color="blue">pivotal clinical study</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can be no assurance that the data from these <font color="blue">clinical trials</font> will support     FDA clearance or approval to market this product for the <font color="blue">designated use</font></td>
    </tr>
    <tr>
      <td>We are currently <font color="blue">manufacturing</font> VITOSS Bone Graft Substitute and CORTOSS in     the US, <font color="blue">distributing</font> VITOSS Bone Graft Substitute, VITAGEL and IMBIBE in     the US, and <font color="blue">distributing</font> VITOSS Bone Graft                                           25     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font>Substitute, CORTOSS and ALIQUOT outside the US We are <font color="blue">manufacturing</font> IMBIBE     and ALIQUOT <font color="blue">in the US </font>through outside third-party contract <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>In  addition,  under  our <font color="blue">agreement</font>, Kensey has the exclusive right to     <font color="blue">manufacture</font> any approved or <font color="blue">cleared jointly</font> developed <font color="blue">products under</font> the     <font color="blue">agreement</font>, including the VITOSS FOAM <font color="blue">product platform</font></td>
    </tr>
    <tr>
      <td>In March 2005, the     <font color="blue">initial term</font> of the <font color="blue">agreement</font> was <font color="blue">extended by amendment</font> for an <font color="blue">additional</font>     three  years to 2014</td>
    </tr>
    <tr>
      <td>VITAGEL and CELLPAKER will be <font color="blue">manufacture</font>d by us     following FDA approval</td>
    </tr>
    <tr>
      <td>VITOSS  Bone  Graft  Substitute, as well as any other products that we     <font color="blue">manufacture</font> or <font color="blue">distribute following</font> their approval or <font color="blue">clearance by</font> the FDA,     including VITAGEL if we are <font color="blue">approved as</font> a <font color="blue">manufacture</font>r, will be subject to     extensive <font color="blue">regulation by</font> the FDA If safety or <font color="blue">efficacy problems</font> occur after     the <font color="blue">product reaches</font> the market, the FDA <font color="blue">may impose severe limitations on</font> the     use of the product</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">modifications</font> to the approved or cleared     <font color="blue">product may</font> require the submission of a new 510(k) notification or premarket     approval <font color="blue">application</font> or premarket <font color="blue">application</font> supplement</td>
    </tr>
    <tr>
      <td>We may not be     successful in obtaining approval to market the <font color="blue">modified product</font> in a timely     manner, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Noncompliance </font>with applicable <font color="blue">requirements</font> can result in,     among other things, fines, injunctions, civil penalties, recall or seizure     of products, total or <font color="blue">partial suspension</font> of production, failure of the     <font color="blue">government</font> to <font color="blue">grant premarket clearance</font> or <font color="blue">premarket approval</font> for devices,     withdrawal of <font color="blue">marketing approvals</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td><font color="blue">International  </font>sales  of  <font color="blue">medical devices</font> are subject to the     <font color="blue">regulatory</font> <font color="blue">requirements</font> of <font color="blue">each country</font> in which the products are sold</td>
    </tr>
    <tr>
      <td>Accordingly, the <font color="blue">introduction</font> of our products in markets outside the United     States  will be subject to <font color="blue"><font color="blue">regulatory</font> approval</font>s or <font color="blue">clearances</font> in those     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> review process varies from country to country</td>
    </tr>
    <tr>
      <td>Many  countries  also impose product standards, packaging and labeling     <font color="blue">requirements</font> and import <font color="blue">restrictions</font> on <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>In addition, each     country has its own tariff <font color="blue">regulations</font>, duties and tax <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The     approval or <font color="blue">clearance by</font> foreign <font color="blue">government</font> authorities is uncertain and can     be expensive</td>
    </tr>
    <tr>
      <td>Our ability to market our <font color="blue">products could</font> be <font color="blue">substantially</font>     limited due to delays in receipt of, or failure to receive, the <font color="blue">necessary</font>     approvals or <font color="blue">clearances</font></td>
    </tr>
    <tr>
      <td>To market a product     in the <font color="blue">European Union</font>, we must be entitled to affix a CE Certification, an     <font color="blue">international</font>  symbol  of adherence to quality assurance standards and     compliance  with  applicable  European medical device <font color="blue">directives</font></td>
    </tr>
    <tr>
      <td>A CE     Certification <font color="blue">enables us</font> to market a product in all of the countries of the     <font color="blue">European Union</font>, as well as in other countries, such as <font color="blue">Switzerland </font>and     Israel, that have adopted the <font color="blue">European Union</font>’s <font color="blue">regulatory</font> standards</td>
    </tr>
    <tr>
      <td>To     date, we have received a <font color="blue">CE Certification </font>for the use of VITOSS Bone Graft     Substitute  as  a <font color="blue">bone void filler</font> and for the use of CORTOSS in screw     <font color="blue">augmentation</font>  and  vertebral  <font color="blue">augmentation</font> procedures</td>
    </tr>
    <tr>
      <td>There can be no     assurance that we will receive <font color="blue">CE Certifications </font>for CORTOSS for any other     <font color="blue">indications</font> for use or that we will receive <font color="blue">CE Certifications </font>for other     products</td>
    </tr>
    <tr>
      <td>If we do not manage commercial scale <font color="blue">manufacturing</font> <font color="blue">capability</font> and <font color="blue">capacity</font>     for  our  products in <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font> and in a     cost-<font color="blue">effective</font> manner, our <font color="blue">product sales</font> may suffer</td>
    </tr>
    <tr>
      <td>Our  VITOSS  Bone Graft Substitute and CORTOSS Synthetic Cortical Bone     <font color="blue">manufacturing</font> <font color="blue">facilities</font> produce <font color="blue">commercial products</font> and are currently     <font color="blue">certified as meeting</font> the <font color="blue">requirements</font> of ISO 9001: 2000 for the period     March 23, 2004 through March 22, 2007 and <font color="blue">European Norm </font>13485 for the period     July 1, 2003 through July 1, 2006, and are subject to <font color="blue">inspection by</font> the FDA     for <font color="blue">compliance with</font> FDA device <font color="blue">manufacture</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition to the     need  for  <font color="blue">regulatory</font>  approval  in  the US for CORTOSS, in order to     <font color="blue">commercialize</font> CORTOSS in the US, its <font color="blue">manufacturing</font> <font color="blue">facility</font> and quality     assurance system must first pass <font color="blue">inspection by</font> the <font color="blue">FDA On November </font>30,     2005, we submitted a <font color="blue">Duplicate PMA </font>for VITAGEL to the FDA through a Grant of     License from <font color="blue">Angiotech </font>to reference their PMA FDA approval of the PMA     <font color="blue">submitted by us</font>, if obtained, <font color="blue">will allow us</font> to sell VITAGEL product that is     <font color="blue">manufacture</font>d on-site in our Malvern, <font color="blue">Pennsylvania </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>    31, 2005, we had included in inventory VITAGEL valued at dlra653cmam835 that was     <font color="blue">manufacture</font>d on-site at our Malvern <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We have no                                           26     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>assurance that we will obtain FDA approval to sell VITAGEL <font color="blue">manufacture</font>d by     us prior to our <font color="blue">current supply</font> of VITAGEL being exhausted</td>
    </tr>
    <tr>
      <td>We may not have     <font color="blue">sufficient inventory</font> of VITAGEL during the <font color="blue">second half</font> of 2006 to support     <font color="blue">customer demand</font></td>
    </tr>
    <tr>
      <td>Our  product  sales  depend  upon,  among other things, our ability to     <font color="blue">manufacture</font>  our products in <font color="blue">commercial quantities</font>, in <font color="blue">compliance with</font>     <font color="blue">regulatory</font> <font color="blue">requirements</font> and in a cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of     our products is subject to regulation and periodic <font color="blue">inspection by</font> the FDA and     other <font color="blue">regulatory</font> bodies for <font color="blue">compliance with</font> quality standards</td>
    </tr>
    <tr>
      <td>There can be     no assurance that the <font color="blue">regulatory</font> authorities will not, during the course of     an inspection of existing or <font color="blue">new <font color="blue">facilities</font></font>, identify what they consider to     be <font color="blue">deficiencies</font> in meeting the <font color="blue">applicable standards</font> and request or seek     <font color="blue">remedial action</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> such <font color="blue">regulations</font> or a delay in <font color="blue">attaining compliance</font>     may result in:         •   <font color="blue">warning letters</font>;         •   <font color="blue">injunctions suspending</font> our <font color="blue">manufacture</font> of products;         •   civil and <font color="blue">criminal penalties</font>;         •   refusal to grant <font color="blue">premarket approval</font>s or <font color="blue">clearances</font>, <font color="blue">CE Certifications </font>or     <font color="blue">clearances</font> to products that are subject to future or pending <font color="blue">submissions</font>;         •   product recalls or seizures of products; and         •   total or <font color="blue">partial suspension</font>s of production</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> a limited number of <font color="blue">specialty suppliers</font> of <font color="blue">certain raw</font>     materials</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">manufacture</font> VITOSS Bone Graft Substitute and CORTOSS and to     have VITOSS FOAM and VITAGEL <font color="blue">manufacture</font>d for us is <font color="blue">dependent on</font> a limited     number of <font color="blue">specialty suppliers</font> of <font color="blue"><font color="blue">certain raw</font> materials</font></td>
    </tr>
    <tr>
      <td>The failure of a     supplier  to continue to <font color="blue">provide us with</font> these materials at a price or     quality acceptable to us, or at all, would have a material adverse effect on     our ability to <font color="blue">manufacture</font> these products</td>
    </tr>
    <tr>
      <td>Moreover, our failure to maintain     <font color="blue">strategic reserve supplies</font> of each <font color="blue">significant</font> single-sourced material used     to <font color="blue">manufacture</font> VITOSS Bone Graft Substitute, CORTOSS and certain products     that we may develop in the <font color="blue">future may</font> result in a breach of our material     financing <font color="blue">agreement</font> with <font color="blue">Royalty Trust</font></td>
    </tr>
    <tr>
      <td>Although we believe that we maintain     good <font color="blue">relationships with</font> our suppliers, there can be no guarantee that such     supplies and services <font color="blue">will continue</font> to be <font color="blue">available with respect</font> to our     current and future <font color="blue">commercialize</font>d products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> Kensey and other third-party <font color="blue">manufacture</font>rs for the     supply of products that we may sell</td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacture</font> of our products is subject to regulation and periodic     <font color="blue">inspection by</font> various <font color="blue">regulatory</font> bodies for <font color="blue">compliance with</font> current FDA     Quality  System  Regulation and <font color="blue">requirements</font>, and EU MDD <font color="blue">International  </font>   Organization  for  Standardization  (“ISO”)  9000 Series standards and     equivalent <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our  24cmam800  square  foot  VITOSS  Bone  Graft  Substitute and CORTOSS     <font color="blue">manufacturing</font> <font color="blue">facilities</font> which produce our <font color="blue">commercial products</font>, are leased     through July 2012 and are <font color="blue">certified as meeting</font> the <font color="blue">requirements</font> of ISO 9000:     2000 for the period March 22, 2004 through March 22, 2007, and <font color="blue">European Norm </font>    (“EN”)  13485  for the period July 1, 2003 through July 1, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">facilities</font> are subject to <font color="blue">inspection by</font> the FDA for <font color="blue">compliance with</font> FDA     device <font color="blue">manufacture</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The most recent FDA inspection resulted     <font color="blue">with no corrective actions</font> being required</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>We  believe our <font color="blue">manufacturing</font> <font color="blue">facilities</font> have the <font color="blue">capacity</font> to meet our     commercial needs for the <font color="blue">next several years</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">manufacturing</font> VITAGEL,     CELLPAKER, IMBIBE, ENDOSKELETON TA, and ALIQUOT through outside third-party     contract <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Our VITOSS Bone Graft Substitute is converted to     VITOSS  FOAM  by  Kensey,  our  <font color="blue">development</font>  partner</td>
    </tr>
    <tr>
      <td>Our third-party     <font color="blue">manufacture</font>rs are ISO 9001 certified or <font color="blue">otherwise meet</font> our <font color="blue">quality system</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition to the need for CORTOSS US <font color="blue"><font color="blue">regulatory</font> approval</font>     in order to <font color="blue">commercialize</font> CORTOSS in the US, the CORTOSS <font color="blue">manufacturing</font>     <font color="blue">facility</font> and quality assurance system must pass <font color="blue">inspection by</font> the FDA     <font color="blue">Angiotech </font> decided  to  cease to <font color="blue">manufacture</font> VITAGEL by November 2005;     therefore, in October 2005, we purchased all <font color="blue">available existing products</font>,     <font color="blue">accessories</font> and work-in-process from <font color="blue">Angiotech </font>for dlra1cmam800cmam000, which is     expected to be sufficient to meet our operating <font color="blue">requirements</font> through mid     2006</td>
    </tr>
    <tr>
      <td>Additionally, on November 30, 2005, we submitted a <font color="blue">Duplicate PMA </font>for     VITAGEL to the FDA through a <font color="blue">Grant of License </font>from <font color="blue">Angiotech </font>to reference     their PMA FDA approval of the PMA <font color="blue">submitted by us</font>, if obtained, will allow     us to sell VITAGEL product that is <font color="blue">manufacture</font>d on-site in our Malvern,     <font color="blue">Pennsylvania </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had included in inventory     VITAGEL valued at dlra653cmam835 that was <font color="blue">manufacture</font>d on-site at our <font color="blue">Malvern     </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We have no assurance that we will obtain FDA approval to sell     VITAGEL <font color="blue">manufacture</font>d by us prior to our <font color="blue">current supply</font> of VITAGEL being     exhausted</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient inventory</font> of VITAGEL during the second     half of 2006 to support <font color="blue">customer demand</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">manufacture</font> our products is <font color="blue">dependent on</font> a limited number of     <font color="blue">specialty suppliers</font> of <font color="blue"><font color="blue">certain raw</font> materials</font></td>
    </tr>
    <tr>
      <td>We have a long-term supply     <font color="blue">agreement</font> which provides bovine collagen for the <font color="blue">manufacture</font> of VITAGEL;     however,  we do not have any other long-term supply <font color="blue">agreement</font>s for raw     materials</td>
    </tr>
    <tr>
      <td>The failure of a supplier to continue to <font color="blue">provide us with</font> these     materials at a price or quality acceptable to us, or at all, would have a     material  adverse effect on our ability to <font color="blue">manufacture</font> these products</td>
    </tr>
    <tr>
      <td>Moreover, our failure to continue to maintain <font color="blue">strategic reserve supplies</font> of     each <font color="blue">significant</font> single-sourced material used to <font color="blue">manufacture</font> VITOSS Bone     Graft Substitute, CORTOSS and certain products that we may develop in the     <font color="blue">future may</font> result in a breach of our material financing <font color="blue">agreement</font> with     <font color="blue">Royalty Trust</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of     our products is subject to regulation and periodic <font color="blue">inspection by</font> various     <font color="blue">regulatory</font> bodies for <font color="blue">compliance with</font> quality standards</td>
    </tr>
    <tr>
      <td>There can be no     assurance that the <font color="blue">regulatory</font> authorities will not, during the course of an     inspection of existing or <font color="blue">new <font color="blue">facilities</font></font>, identify what they consider to be     <font color="blue">deficiencies</font>  in  meeting the <font color="blue">applicable standards</font> and request or seek     <font color="blue">remedial action</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> such <font color="blue">regulations</font> or a delay in <font color="blue">attaining compliance</font>     may result in:           •   <font color="blue">warning letters</font>;           •   <font color="blue">injunctions suspending</font> our <font color="blue">manufacture</font> of products;           •   civil and <font color="blue">criminal penalties</font>;           •   refusal to grant <font color="blue">premarket approval</font>s, <font color="blue">CE Certifications </font>or <font color="blue">clearances</font>     to products that are subject to future or pending <font color="blue">submissions</font>;           •   product recalls or seizures of products; and           •   total or <font color="blue">partial suspension</font>s of production</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">difficult</font>ies</font> of operating in <font color="blue"><font color="blue">international</font> markets</font> may harm sales of our     products</td>
    </tr>
    <tr>
      <td>The   <font color="blue">international</font>  nature  of  our  business  subjects  us  and  our     <font color="blue">representatives</font>, agents and <font color="blue"><font color="blue">distributor</font>s</font> to the laws and <font color="blue">regulations</font> of the     <font color="blue">jurisdictions</font> in which they operate, and in which our products are sold</td>
    </tr>
    <tr>
      <td>The     types of risks that we face in <font color="blue">international</font> <font color="blue">operations</font> include:         •   the imposition of <font color="blue">government</font>al controls;                                           28     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>•   logistical <font color="blue"><font color="blue">difficult</font>ies</font> in managing <font color="blue">international</font> <font color="blue">operations</font>; and         •   <font color="blue">fluctuations</font> in <font color="blue">foreign currency exchange rates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> sales and <font color="blue">operations</font> may be limited or disrupted if we     <font color="blue">cannot successfully meet</font> the <font color="blue">challenges</font> of operating <font color="blue">international</font>ly</td>
    </tr>
    <tr>
      <td>If  <font color="blue">losses continue</font> in the long term, it <font color="blue">could limit</font> our growth in the     <font color="blue">orthopedic industry</font> and <font color="blue">jeopardize</font> our viability</td>
    </tr>
    <tr>
      <td>We have experienced negative operating <font color="blue">cash flows since</font> our inception and     have funded our <font color="blue">operations</font> primarily from proceeds received from sales of     our  stock</td>
    </tr>
    <tr>
      <td>In July 2004, we raised approximately dlra24dtta0 million in net     <font color="blue">proceeds from</font> the sale of 5cmam681cmam818 shares of our <font color="blue"><font color="blue">Common Stock</font> </font>to <font color="blue">Angiotech </font>    and, in <font color="blue">December </font>2005, we raised an aggregate of approximately dlra12dtta9 million     in net <font color="blue">proceeds from</font> the sale of 4cmam318cmam182 shares of our <font color="blue"><font color="blue">Common Stock</font> </font>to     <font color="blue">institutional</font> investors</td>
    </tr>
    <tr>
      <td>We believe our existing cash, <font color="blue">cash equivalent</font>s, and     <font color="blue"><font color="blue">investment</font>s</font> of dlra27cmam672cmam221 as of <font color="blue">December </font>31, 2005 will be sufficient to     meet our currently estimated operating and investing <font color="blue">requirements</font> for at     least the <font color="blue">next twelve months</font></td>
    </tr>
    <tr>
      <td>To date, we have not <font color="blue">been profitable</font></td>
    </tr>
    <tr>
      <td>We have     incurred  substantial  operating  losses  since  our  inception and at     <font color="blue">December </font>31, 2005, had an <font color="blue">accumulated deficit</font> of dlra118cmam574cmam135</td>
    </tr>
    <tr>
      <td>These losses     have resulted <font color="blue">principally from</font>:         •   the <font color="blue">development</font> and patenting of our <font color="blue">technologies</font>;         •   pre-clinical and <font color="blue">clinical studies</font>;         •   <font color="blue">preparation</font> of <font color="blue">submissions</font> to the FDA and foreign <font color="blue">regulatory</font> bodies; and         •   the <font color="blue">development</font> of <font color="blue">manufacturing</font>, sales and marketing <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We expect to continue to incur <font color="blue">significant</font> operating losses in the future as     we continue our product <font color="blue">development</font> efforts, expand our marketing and sales     <font color="blue">activities</font> and further develop our <font color="blue">manufacturing</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We may not     ever successfully <font color="blue">commercialize</font> our products in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may never be     able to achieve or maintain <font color="blue">profitability</font> in the future and our <font color="blue">products may</font>     never be <font color="blue">commercially accepted</font> or generate sufficient <font color="blue">product sales</font> to fund     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to meet our <font color="blue"><font color="blue">obligation</font>s</font> under a <font color="blue">revenue sharing <font color="blue">agreement</font></font>, we may     be required to <font color="blue">repurchase from</font> an investor its right to receive <font color="blue">revenues on</font>     certain of our <font color="blue">product sales</font>, and the <font color="blue">investor could foreclose on certain</font>     assets that are essential to our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">During October </font>2001, we completed a dlra10cmam000cmam000 product <font color="blue">development</font> and     <font color="blue">equity financing with</font> Paul Capital Royalty Acquisition Fund, LP, which was     <font color="blue">subsequently assigned</font> to <font color="blue">Royalty Trust</font></td>
    </tr>
    <tr>
      <td>In this financing, we sold Royalty     Trust  a  <font color="blue">revenue interest</font> and shares of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>The revenue     interest  provides  for  Royalty  Trust  to  receive 3dtta5prca on the first     dlra100cmam000cmam000  of  annual sales plus 1dtta75prca of annual sales in excess of     dlra100cmam000cmam000 of certain of our products, including VITOSS, CORTOSS and any     <font color="blue">structural bioactive</font> device developed, in <font color="blue">North America and Europe </font>through     2016, subject to <font color="blue">certain adjustments</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">revenue interest</font> percentage can     increase if we fail to <font color="blue">meet contractually specified levels</font> of <font color="blue">annual net</font>     sales of products for which <font color="blue">Royalty Trust</font> is entitled to receive its revenue     interest</td>
    </tr>
    <tr>
      <td>We do not currently expect that changes in the <font color="blue">revenue interest</font>     percentage resulting from <font color="blue">fluctuations</font> in sales of products subject to the     <font color="blue">revenue interest</font> will have a material effect on operating results for a     period when considered relative to sales of the products for that period</td>
    </tr>
    <tr>
      <td><font color="blue">Throughout </font>the term of the <font color="blue">Royalty Trust</font> <font color="blue">revenue interest</font> <font color="blue">agreement</font>, we are     required to make <font color="blue"><font color="blue">advance payment</font>s on</font> the <font color="blue">revenue interest</font> <font color="blue">obligation</font> at the     beginning of <font color="blue">each year</font></td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2004, the <font color="blue">revenue interest</font> assignment     <font color="blue">agreement</font> with <font color="blue">Royalty Trust</font> was amended by mutual <font color="blue">agreement</font> to reduce the     <font color="blue">advance payment</font> for 2004 from dlra2cmam000cmam000 to dlra1cmam100cmam000</td>
    </tr>
    <tr>
      <td>Of the dlra1cmam100cmam000     paid  to <font color="blue">Royalty Trust</font>, dlra837cmam844 was earned in 2004 and the balance of     dlra262cmam154  was  included  in  prepaid  revenue  <font color="blue">interest expense on</font> the     <font color="blue">accompanying consolidated balance sheet as</font> of <font color="blue">December </font>31, 2004, and was     repaid to us during the <font color="blue">first quarter</font> of 2005</td>
    </tr>
    <tr>
      <td><font color="blue">In                                           </font>29     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>February 2005, the <font color="blue">revenue interest</font> assignment <font color="blue">agreement</font> with <font color="blue">Royalty Trust</font>     was amended by mutual <font color="blue">agreement</font> to reduce the <font color="blue">advance payment</font> for 2005 from     dlra3cmam000cmam000 to dlra1cmam600cmam000</td>
    </tr>
    <tr>
      <td>Of the dlra1cmam600cmam000 paid to <font color="blue">Royalty Trust</font>, dlra989cmam287     was earned in 2005 and the balance of dlra610cmam713 was included in prepaid     <font color="blue">revenue interest</font> expense on the <font color="blue">accompanying consolidated balance sheet as</font>     of <font color="blue">December </font>31, 2005, and is scheduled to be repaid to us in April of 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, the <font color="blue">revenue interest</font> assignment <font color="blue">agreement</font> with Royalty     Trust was again amended by mutual <font color="blue">agreement</font> to reduce the <font color="blue">advance payment</font>     for 2006 from dlra3cmam000cmam000 to dlra1cmam750cmam000, which was paid to <font color="blue">Royalty Trust</font>     during January 2006</td>
    </tr>
    <tr>
      <td>While we believe that we will have     <font color="blue">sufficient cash</font> at the end of 2006 to make the required dlra3cmam000cmam000 advance     payments to <font color="blue">Royalty Trust</font> during 2007, we cannot be certain that we will     have <font color="blue">sufficient cash</font> to meet our <font color="blue">advance payment</font> <font color="blue"><font color="blue">obligation</font>s</font> for the years     2008 through 2016</td>
    </tr>
    <tr>
      <td>Advance <font color="blue">payments impact cash flow</font> when made, and they     <font color="blue">affect earnings only as</font> the <font color="blue">advance payment</font>s are credited <font color="blue">within each period</font>     against the <font color="blue">revenue interest</font> actually earned by <font color="blue">Royalty Trust</font> during that     year, with any excess <font color="blue">advance payment</font>s refunded to us shortly after the end     of the year</td>
    </tr>
    <tr>
      <td>Our <font color="blue">obligation</font> to pay the <font color="blue">revenue interest</font> is <font color="blue">secured by</font> our licenses,     patents and <font color="blue">trademarks</font> relating to certain of our products, including VITOSS     Bone  Graft  Substitute,  CORTOSS  and any <font color="blue">structural bioactive</font> device     developed, in North America and Europe, and the 12prca <font color="blue">revenue interest</font> we pay     to  one of our wholly-owned subsidiaries, on the sales of our products     (<font color="blue">collectively</font>, the “<font color="blue">Pledged Assets</font>”)</td>
    </tr>
    <tr>
      <td>We are also required to maintain:           •   Cash, <font color="blue">cash equivalent</font> and <font color="blue"><font color="blue">investment</font> balances</font> equal to or <font color="blue">greater than</font>     the product of (i) 1dtta5 and (ii) total operating losses, net of non-cash     charges, for the <font color="blue">preceding fiscal quarter</font>; and           •   total <font color="blue">shareholder</font>s’ equity of at least dlra8cmam664cmam374; provided, however,     that under the provisions of the <font color="blue">agreement</font> with <font color="blue">Royalty Trust</font>, when     calculating <font color="blue">shareholder</font>s’ equity for the purposes of the financial     covenants, the <font color="blue">revenue interest</font> <font color="blue">obligation</font> is included in <font color="blue">shareholder</font>s’     equity at its carrying value</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we were in <font color="blue">compliance with</font> all <font color="blue">financial covenants</font></td>
    </tr>
    <tr>
      <td>However, if we fail to maintain <font color="blue">such balances</font> and <font color="blue">shareholder</font>s’ equity,     <font color="blue">Royalty Trust</font> can demand that we repurchase its <font color="blue">revenue interest</font></td>
    </tr>
    <tr>
      <td>In addition to the failure to <font color="blue">comply with</font> the <font color="blue">financial covenants</font> described     above, the occurrence of <font color="blue">certain events</font>, including those set forth below,     triggers <font color="blue">Royalty Trust</font>’s right to require us to repurchase its revenue     interest:           •   a <font color="blue">judicial decision</font> that has a material adverse effect on our     business, <font color="blue">operations</font>, assets or <font color="blue">financial condition</font>;           •   the <font color="blue">acceleration</font> of our <font color="blue"><font color="blue">obligation</font>s</font> or the exercise of default     <font color="blue">remedies by</font> a <font color="blue">secured lender under certain debt instruments</font>;           •   a voluntary or <font color="blue"><font color="blue">involuntary</font> <font color="blue">bankruptcy</font></font> that <font color="blue">involves us</font> or our wholly     owned subsidiary, <font color="blue">Vita Special Purpose Corp</font></td>
    </tr>
    <tr>
      <td>;           •   our insolvency;           •   a change in control of our company; and           •   the breach of a representation, warranty or <font color="blue">certification</font> made by us     in the <font color="blue">agreement</font>s with <font color="blue">Royalty Trust</font> that, <font color="blue">individually</font> or in the aggregate,     <font color="blue">would reasonably</font> be expected to have a material adverse effect on our     business, <font color="blue">operations</font>, assets or <font color="blue">financial condition</font>, and such breach is not     cured within 30 days after notice <font color="blue">thereof from</font> <font color="blue">Royalty Trust</font></td>
    </tr>
    <tr>
      <td>In addition, our failure to maintain <font color="blue">strategic reserve supplies</font> of each     <font color="blue">significant</font> single-source material used to <font color="blue">manufacture</font> VITOSS Bone Graft     Substitute, CORTOSS and certain products that we may develop in the future     may result in a breach of our material financing <font color="blue">agreement</font> with Royalty     Trust</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient cash</font> funds to repurchase the revenue     <font color="blue">interest upon</font> a <font color="blue">repurchase event</font></td>
    </tr>
    <tr>
      <td>The exact amount of the <font color="blue">repurchase price</font>     is <font color="blue">dependent upon</font> certain factors, including when the <font color="blue">repurchase event</font>     occurs</td>
    </tr>
    <tr>
      <td>If a <font color="blue">repurchase event</font> had been                                           30     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>triggered and <font color="blue">Royalty Trust</font> exercised its right to require us to repurchase     its <font color="blue">revenue interest</font> as of <font color="blue">December </font>31, 2005, we would have owed Royalty     Trust dlra19cmam606cmam958</td>
    </tr>
    <tr>
      <td>The <font color="blue">repurchase price</font> for <font color="blue">Royalty Trust</font>’s <font color="blue">revenue interest</font> as of a given date     is <font color="blue">calculated</font> in three steps</td>
    </tr>
    <tr>
      <td>First, a specified annual rate of return (25prca     <font color="blue">effective</font>  October 16, 2005) is applied to <font color="blue">Royalty Trust</font>’s dlra10cmam000cmam000     <font color="blue">original purchase price from</font> October 16, 2001 to the date of <font color="blue">determination</font>     of the <font color="blue">repurchase price</font></td>
    </tr>
    <tr>
      <td>Second, the result obtained from the first step of     the <font color="blue">calculation</font> is added to the original dlra10cmam000cmam000 purchase price</td>
    </tr>
    <tr>
      <td>Third,     the sum obtained from the second step of the <font color="blue">calculation</font> is <font color="blue">reduced by both</font>     dlra3cmam333cmam333  and  the <font color="blue">actual amount</font> of <font color="blue">revenue interest</font> paid during the     <font color="blue">specified period</font></td>
    </tr>
    <tr>
      <td>If we were unable to repurchase the <font color="blue">revenue interest</font> upon a repurchase     event, <font color="blue">Royalty Trust</font> could foreclose on the <font color="blue">Pledged Assets</font>, and we could be     forced into <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td><font color="blue">Royalty Trust</font> <font color="blue">could also foreclose on</font> the Pledged     Assets if we <font color="blue">became insolvent</font> or involved in a voluntary or <font color="blue">involuntary</font>     <font color="blue">bankruptcy</font> proceeding</td>
    </tr>
    <tr>
      <td>No <font color="blue">repurchase event</font>s or <font color="blue">foreclosures</font> have occurred as     of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>In the event that we repurchased <font color="blue">Royalty Trust</font>’s     <font color="blue">revenue interest</font>, <font color="blue">Royalty Trust</font> would have no <font color="blue">obligation</font> to surrender the     shares of our <font color="blue"><font color="blue">Common Stock</font> </font>that it had <font color="blue">purchased as</font> part of the revenue     <font color="blue">interests assignment transaction</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> <font color="blue">may fluctuate due</font> to <font color="blue">factors out</font> of our control,     <font color="blue">which could</font> cause <font color="blue">volatility</font> in our stock price</td>
    </tr>
    <tr>
      <td>VITOSS Bone Graft Substitute, IMBIBE, CORTOSS and ALIQUOT are currently our     <font color="blue">only products</font> for which we have received <font color="blue"><font color="blue">regulatory</font> approval</font>s for sale</td>
    </tr>
    <tr>
      <td>VITOSS  Bone  Graft Substitute is cleared for sale <font color="blue">in the US </font>and the     <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>IMBIBE is cleared for sale <font color="blue">in the US </font>CORTOSS and ALIQUOT     are  cleared  for sale in the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>In addition, we obtained     <font color="blue">distribution</font> rights to VITAGEL and CELLPAKER in June 2004 and launched that     product <font color="blue">in the US </font>in January 2005</td>
    </tr>
    <tr>
      <td>Future levels of VITOSS Bone Graft     Substitute, VITAGEL, CORTOSS, ALIQUOT, CELLPAKER and IMBIBE <font color="blue">product sales</font>     are <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>VITOSS Bone Graft Substitute <font color="blue">product sales</font> to date     may not be <font color="blue">indicative</font> of <font color="blue">future <font color="blue">sales levels</font></font></td>
    </tr>
    <tr>
      <td>VITOSS Bone Graft Substitute,     CORTOSS and ALIQUOT <font color="blue">sales levels</font> in Europe <font color="blue">may fluctuate due</font> to <font color="blue">seasonality</font>     of <font color="blue">elective surgeries</font> and the timing of any <font color="blue"><font color="blue">distributor</font> stocking orders</font> and     VITOSS Bone Graft Substitute, VITAGEL, IMBIBE and CELLPAKER <font color="blue">sales levels</font> may     fluctuate <font color="blue">in the US </font>due to <font color="blue">seasonality</font> of <font color="blue">elective surgeries</font> and the     timing of <font color="blue">orders from hospitals</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> may fluctuate     <font color="blue">significant</font>ly in the future as a result of a number of <font color="blue">additional</font> factors,     many of which are outside of our control</td>
    </tr>
    <tr>
      <td>These factors include, but are not     limited to:         •   the timing of <font color="blue">government</font>al approvals or <font color="blue">clearances</font> for our products and     our <font color="blue">competitors</font>’ products;         •   <font color="blue">unanticipated events associated with clinical</font> and pre-<font color="blue">clinical trials</font> of     our products;         •   the <font color="blue">medical <font color="blue">community</font></font>’s <font color="blue">acceptance</font> of our products;         •   the timing in obtaining adequate third-party <font color="blue">reimbursement</font> of our     products;         •   the success of <font color="blue"><font color="blue">competitive</font> products</font>;         •   our ability to enter into <font color="blue">strategic alliances</font> with other companies;         •   expenses associated with <font color="blue">development</font> and protection of <font color="blue">intellectual</font>     <font color="blue">property matters</font>;         •   <font color="blue">establishment</font> of commercial scale <font color="blue">manufacturing</font> <font color="blue">capabilities</font>;         •   <font color="blue">events <font color="blue">affecting</font> logistics</font> and <font color="blue">elective surgery trends</font>;         •   the timing of expenses related to <font color="blue">commercialization</font> of <font color="blue">new products</font>;         •   <font color="blue"><font color="blue">competitive</font> <font color="blue">disruption</font>s</font> to our <font color="blue">distribution</font> channels;         •   the <font color="blue">adequate training</font> of a sufficient number of surgeons in the use of     our products;         •   pending or <font color="blue">threatened offers</font> to acquire us; and         •   timing of <font color="blue">government</font>al approvals or <font color="blue">clearances</font> for us to <font color="blue">manufacture</font> the     products we sell</td>
    </tr>
    <tr>
      <td>The results of our <font color="blue">operations</font> may fluctuate <font color="blue">significant</font>ly from quarter to     quarter and may not <font color="blue">meet expectations</font> of <font color="blue">securities analysts</font> and investors</td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>Our business will be damaged if we are unable to protect our <font color="blue">proprietary</font>     rights to our products, and we may be subject to <font color="blue">intellectual</font> property     <font color="blue">infringement</font> claims by others</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">patent protection</font>, as well as a <font color="blue">combination</font> of copyright, trade     secret and trademark laws, nondisclosure and confidentiality <font color="blue">agreement</font>s and     other  contractual <font color="blue">restrictions</font> to protect our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However,  these  measures  afford  only limited protection and may not     <font color="blue">adequately protect</font> our rights</td>
    </tr>
    <tr>
      <td>For example, our <font color="blue">patents may</font> be challenged,     invalidated or <font color="blue">circumvented by third parties</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we     own or <font color="blue">control eighteen issued</font> US patents and <font color="blue">thirteen pending patent</font>     <font color="blue">application</font>s in the US, and several <font color="blue">counterparts</font> of certain of these     patents and pending patent <font color="blue">application</font>s worldwide, including Canada, Europe,     Mexico and Japan</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">patents will issue from</font> any     of the pending patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Moreover, we cannot be certain that we     were the first creator of inventions covered by pending patent <font color="blue">application</font>s     or we were the first to file patent <font color="blue">application</font>s for the <font color="blue">relevant inventions</font>     for the <font color="blue">following reasons</font>:         •   patent <font color="blue">application</font>s filed prior to <font color="blue">December </font>2000 <font color="blue">in the US </font>are     maintained in <font color="blue">secrecy until issued</font>;         •   patent <font color="blue">application</font>s filed after November 2000 <font color="blue">in the US </font>are maintained     in <font color="blue">secrecy until eighteen months from</font> the date of filing; and         •   the <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature</font>     tends to lag behind actual <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>If  we  do receive a patent, it may not be <font color="blue">broad enough</font> to protect our     <font color="blue">proprietary</font> position in the <font color="blue">technology</font> or to be <font color="blue">commercially useful</font> to us</td>
    </tr>
    <tr>
      <td>In addition, if we lose any <font color="blue">key personnel</font>, we may not be able to prevent the     <font color="blue">unauthorized disclosure</font> or use of our <font color="blue">technical knowledge</font> or other trade     secrets  by  those  <font color="blue">former employees</font></td>
    </tr>
    <tr>
      <td>Furthermore, the laws of foreign     countries may not protect our <font color="blue"><font color="blue">intellectual</font> property rights</font> to the same     extent as the laws of the US Finally, even if our <font color="blue">intellectual</font> property     rights are <font color="blue">adequately protect</font>ed, litigation or other <font color="blue">proceedings may</font> be     <font color="blue">necessary</font> to enforce our <font color="blue"><font color="blue">intellectual</font> property rights</font>, <font color="blue">which could</font> result in     substantial costs to us and result in a diversion of <font color="blue">management</font> attention</td>
    </tr>
    <tr>
      <td>If our <font color="blue">intellectual</font> property is not <font color="blue">adequately protect</font>ed, our <font color="blue">competitors</font>     could use the <font color="blue">intellectual</font> property that we have developed to enhance their     products and compete more directly with us, <font color="blue">which could</font> damage our business</td>
    </tr>
    <tr>
      <td>In addition to the risk of failing to <font color="blue">adequately protect</font> our <font color="blue">proprietary</font>     rights,  there is a risk that we may become subject to a claim that we     <font color="blue">infringe upon</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>Although we do not believe     that we are infringing the rights of others, third parties may claim that we     are doing so</td>
    </tr>
    <tr>
      <td>There  is  a  substantial  amount  of <font color="blue">litigation over patent</font> and other     <font color="blue"><font color="blue">intellectual</font> property rights</font> in the medical device industry <font color="blue">generally</font>, and     in the <font color="blue">spinal market segments particularly</font></td>
    </tr>
    <tr>
      <td>If the holder of patents brought     an <font color="blue">infringement</font> action against us, the cost of litigating the claim could be     substantial  and  divert <font color="blue">management</font> attention</td>
    </tr>
    <tr>
      <td>In addition, if a court     determined  that  one  of our <font color="blue">products infringed</font> a patent, we could be     <font color="blue">prevented from selling</font> that <font color="blue">product unless</font> we could obtain a <font color="blue">license from</font>     the owner of the patent</td>
    </tr>
    <tr>
      <td>A <font color="blue">license may</font> not be <font color="blue">available on terms</font> acceptable     to  us,  if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Modification </font>of our products or <font color="blue">development</font> of new     products to avoid <font color="blue">infringement</font> may require us to conduct <font color="blue">additional</font> clinical     trials for these new or <font color="blue">modified product</font>s and to revise our <font color="blue">filings with</font> the     FDA, which is time consuming and expensive</td>
    </tr>
    <tr>
      <td>If we were not successful in     obtaining a license or <font color="blue">redesigning</font> our product, our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>If we cannot keep up with <font color="blue">technological</font> changes and <font color="blue">marketing initiatives</font> of     <font color="blue">competitors</font>, sales of our <font color="blue">products may</font> be harmed</td>
    </tr>
    <tr>
      <td><font color="blue">Extensive </font><font color="blue">research efforts</font> and rapid <font color="blue">technological</font> change <font color="blue">characterize</font> the     market for products in the <font color="blue">orthopedic market</font></td>
    </tr>
    <tr>
      <td>We anticipate that we will     face  intense  <font color="blue">competition</font>  from  medical device, <font color="blue">medical products</font> and     <font color="blue">pharmaceutical companies</font></td>
    </tr>
    <tr>
      <td>For instance, several PMMA <font color="blue">bone cement</font> received     510(k) clearance in 2004 for vertebral <font color="blue">augmentation</font> of VCFs</td>
    </tr>
    <tr>
      <td>Further, in     2004, the spinal bone grafting market saw the <font color="blue">introduction</font> of total                                           32     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font><font color="blue">disk replacement devices</font> (TDRs) <font color="blue">as treatment alternative</font> for <font color="blue">degenerative</font>     <font color="blue">disk disease designed</font> to preserve the motion of the vertebrae of the spine</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products could</font> be rendered <font color="blue">non<font color="blue">competitive</font></font> or <font color="blue">obsolete by</font> these and other     <font color="blue">competitors</font>’  <font color="blue">technological</font>  advances</td>
    </tr>
    <tr>
      <td>We may be unable to respond to     <font color="blue">technological</font> advances through the <font color="blue">development</font> and <font color="blue">introduction</font> of new     products</td>
    </tr>
    <tr>
      <td>Moreover, many of our existing and potential <font color="blue">competitors</font> have     <font color="blue">substantially</font>   greater  financial,  marketing,  sales,  <font color="blue">distribution</font>,     <font color="blue">manufacturing</font> and <font color="blue">technological</font> resources than us</td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font> may be     in the process of seeking FDA or other <font color="blue"><font color="blue">regulatory</font> approval</font>s or <font color="blue">clearances</font>,     or <font color="blue">patent protection</font>, for <font color="blue"><font color="blue">competitive</font> products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> could,     therefore, <font color="blue">commercialize</font> competing products in advance of our products</td>
    </tr>
    <tr>
      <td><font color="blue">They     </font><font color="blue">may also enjoy</font> substantial <font color="blue">advantages over us</font> in terms of:         •   research and <font color="blue">development</font> expertise;         •   experience in conducting <font color="blue">clinical trials</font>;         •   experience in <font color="blue">regulatory</font> matters;         •   <font color="blue">manufacturing</font> efficiency;         •   <font color="blue">name recognition</font>;         •   sales and <font color="blue">marketing expertise</font>;         •   established <font color="blue">distribution</font> channels; and         •   established <font color="blue">relationships with</font> health care providers and payors</td>
    </tr>
    <tr>
      <td>These <font color="blue">advantages may <font color="blue">adversely affect</font></font> our plans for market <font color="blue">acceptance</font> of our     products</td>
    </tr>
    <tr>
      <td>We  may  acquire  <font color="blue">technologies</font>  or  companies in the future, and these     <font color="blue">acquisition</font>s could result in dilution to our <font color="blue">shareholder</font>s and <font color="blue">disruption</font> of     our business</td>
    </tr>
    <tr>
      <td>Entering into an <font color="blue">acquisition</font> could divert <font color="blue">management</font> attention</td>
    </tr>
    <tr>
      <td>We also     could fail to assimilate the acquired company, <font color="blue">which could</font> lead to higher     operating expenses</td>
    </tr>
    <tr>
      <td>Finally, our <font color="blue">shareholder</font>s could be diluted if we issue     shares of our stock to acquire another company or <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>33     ______________________________________________________________________    [55]Table of <font color="blue">Contents       </font>Provisions of <font color="blue">Pennsylvania </font>law or our <font color="blue">Articles of Incorporation </font>may deter a     <font color="blue"><font color="blue">third party</font> from seeking</font> to obtain control of us or may affect your rights     as a <font color="blue">shareholder</font></td>
    </tr>
    <tr>
      <td>Certain provisions of <font color="blue">Pennsylvania </font>law could make it more <font color="blue">difficult</font> for a     <font color="blue">third party</font> to acquire us, or <font color="blue">could discourage</font> a <font color="blue">third party</font> from attempting     to acquire us</td>
    </tr>
    <tr>
      <td>These provisions <font color="blue">could limit</font> the price that <font color="blue">certain investors</font>     might be willing to pay in the future for shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue">Articles of Incorporation </font>enable our board of <font color="blue">directors</font> to     issue up to 20cmam000cmam000 shares of <font color="blue">preferred stock</font> having rights, privileges     and <font color="blue">preferences as</font> are determined by the board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Accordingly,     our board is empowered, without <font color="blue">shareholder</font> approval, to <font color="blue">issue preferred</font>     stock  with  dividend, liquidation, conversion, voting or other rights     superior to those of our common <font color="blue">shareholder</font>s</td>
    </tr>
    <tr>
      <td>For example, an issuance of     <font color="blue">preferred stock</font> could:           •   <font color="blue">adversely affect</font> the <font color="blue">voting power</font> of the common <font color="blue">shareholder</font>s;           •   make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to <font color="blue">gain control</font> of us;           •   <font color="blue">discourage bids</font> for our <font color="blue">common stock</font> at a premium; or           •   otherwise <font color="blue">adversely affect</font> the <font color="blue">market price</font> of the <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price may</font> be volatile</td>
    </tr>
    <tr>
      <td>Our stock price, like that of many small cap medical <font color="blue">technology</font> companies,     may be volatile</td>
    </tr>
    <tr>
      <td>In general, equity markets, including Nasdaq, have from     time to time experienced <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font> that are     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>These broad     market <font color="blue">fluctuations</font> may <font color="blue">adversely affect</font> the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors could also</font> cause our stock price to be volatile     or decrease:         •   <font color="blue">fluctuations</font> in our results of <font color="blue">operations</font>;         •   under-performance in relation to analysts’ estimates or financial     <font color="blue">guidance provided by us</font>;         •   changes in the <font color="blue">financial guidance</font> we provide to the <font color="blue">investment</font>     <font color="blue">community</font>;         •   changes in <font color="blue">stock market analyst recommendations</font> regarding our stock;         •   <font color="blue">announcements</font> of <font color="blue">technological</font> innovations or <font color="blue">new products</font> by us or our     <font color="blue">competitors</font>;         •   issues in <font color="blue">establishing</font> commercial scale <font color="blue">manufacturing</font> <font color="blue">capabilities</font>;         •   <font color="blue">disruption</font>s with the <font color="blue">manufacturing</font> of our products, including with     respect to our third-party <font color="blue">manufacture</font>rs;         •   <font color="blue">unanticipated events associated with clinical</font> and pre-<font color="blue">clinical trials</font>;         •   FDA and <font color="blue">international</font> <font color="blue">regulatory</font> actions regarding us or our     <font color="blue">competitors</font>;         •   <font color="blue">determination</font>s by <font color="blue">government</font>s and insurance companies regarding     <font color="blue">reimbursement</font> for medical <font color="blue">procedures using</font> our or our <font color="blue">competitors</font>’ products;         •   the <font color="blue">medical <font color="blue">community</font></font>’s <font color="blue">acceptance</font> of our products;         •   <font color="blue">product sales</font> growth rates;         •   <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">establishing</font> and expanding our <font color="blue">distribution</font> channels;         •   <font color="blue">disruption</font>s to our <font color="blue">distribution</font> channels as a result of <font color="blue">competitive</font>     market changes;         •   product recalls;         •   <font color="blue">development</font>s with respect to patents or <font color="blue">proprietary</font> rights;         •   public concern as to the safety of products developed by us or by     others;         •   changes in <font color="blue">health care policy</font> in the <font color="blue">United States </font>and <font color="blue">international</font>ly;         •   <font color="blue">acquisition</font>s or <font color="blue">strategic alliances</font> by us or our <font color="blue">competitors</font>;         •   business <font color="blue">conditions</font> <font color="blue">affecting</font> other medical device companies or the     medical device industry <font color="blue">generally</font>;         •   general market <font color="blue">conditions</font>, particularly for <font color="blue">companies with</font> small market     <font color="blue">capitalizations</font>; and         •   pending or <font color="blue">threatened offers</font> to acquire us</td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________    [56]Table of <font color="blue">Contents       </font>If we are sued in a <font color="blue">product <font color="blue">liability</font> action</font>, we could be forced to pay     substantial damages and the attention of our <font color="blue">management</font> team may be diverted     from operating our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> <font color="blue">medical devices</font> that are <font color="blue">used on patients</font> in surgery, and we     may be subject to a <font color="blue">product <font color="blue">liability</font> lawsuit</font></td>
    </tr>
    <tr>
      <td>In particular, the market for     <font color="blue">spine products</font> has a history of <font color="blue">product <font color="blue">liability</font> litigation</font></td>
    </tr>
    <tr>
      <td>Under certain     of our <font color="blue">agreement</font>s with our <font color="blue"><font color="blue">distributor</font>s</font> and <font color="blue">sales agencies</font>, we indemnify the     <font color="blue">distributor</font> or <font color="blue">sales agency from product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>Any product     <font color="blue">liability</font> claim <font color="blue">brought against us</font>, with or without merit, could result in     the increase of our product <font color="blue">liability</font> insurance rates or the <font color="blue">inability</font> to     <font color="blue">secure coverage</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, we would have to pay any amount     <font color="blue">awarded by</font> a court in excess of <font color="blue">policy limits</font></td>
    </tr>
    <tr>
      <td>We maintain product <font color="blue">liability</font>     insurance in the <font color="blue">annual aggregate amount</font> of up to dlra10 million, although our     <font color="blue">insurance policies</font> have <font color="blue">various exclusions</font></td>
    </tr>
    <tr>
      <td>Thus, we may be subject to a     product <font color="blue">liability</font> claim for which we have no <font color="blue">insurance coverage</font>, in which     case we may have to pay the <font color="blue">entire amount</font> of any award</td>
    </tr>
    <tr>
      <td>A meritless or <font color="blue">unsuccessful</font> product     <font color="blue">liability</font> claim would be time-consuming and expensive to defend and could     result in the diversion of <font color="blue">management</font>’s attention from our core business</td>
    </tr>
    <tr>
      <td>A     successful product <font color="blue">liability</font> claim or series of claims <font color="blue">brought against us</font> in     excess of our <font color="blue">coverage could</font> have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">could suffer</font> if we <font color="blue">cannot attract</font> and retain the services of     <font color="blue">key employees</font></td>
    </tr>
    <tr>
      <td>We depend <font color="blue">substantially</font> upon the <font color="blue">continued service</font> and performance of our     <font color="blue">existing executive officers</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">key personnel</font> in <font color="blue">formulating</font> and     <font color="blue">implementing</font>  our  product research, <font color="blue">development</font> and <font color="blue">commercialization</font>     strategies</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in large part on our ability to attract     and retain <font color="blue">highly skilled employees</font></td>
    </tr>
    <tr>
      <td>We compete for <font color="blue">such personnel with</font>     other  companies, academic institutions, <font color="blue">government</font> entities and other     <font color="blue">organization</font>s</td>
    </tr>
    <tr>
      <td>If one or more of our <font color="blue">key employees</font> resigns, the loss of that     <font color="blue">employee could harm</font> our business</td>
    </tr>
    <tr>
      <td>If we lose any <font color="blue">key personnel</font>, we may not     be able to prevent the <font color="blue">unauthorized disclosure</font> or use of our technical     knowledge or other <font color="blue">trade secrets by</font> those <font color="blue">former employees</font>, despite our use     of confidentiality <font color="blue">agreement</font>s</td>
    </tr>
  </tbody>
</table>